Global
Contact Us
DKSH has entered into a strategic partnership with Osteopore to provide comprehensive commercial and logistics services for its advanced regenerative dental product portfolio in Malaysia. This collaboration reinforces DKSH’s commitment to expanding access to innovative medical technologies while strengthening Osteopore’s presence in the Malaysian dental market.
Net sales of CHF 11.1 billion (2.9% at CER1) – growth acceleration in H2 2025 (+3.6% CER1) Core EBIT increased to CHF 349.0 million (6.7% at CER1) – stronger H2 2025 (+8.1% CER1) Core EBIT margin expanded by 0.1 percentage points to 3.2% (5th consecutive year) Free Cash Flow of CHF 215.5 million Dividend proposal of CHF 2.50 per share (+6.4%)2 and 9 M&A transactions announced in 2025 Mid-term roadmap confirmed
DKSH has entered into a partnership with Pfizer to commercialize and distribute its anti‑infective therapies, marking a significant milestone in strengthening Malaysia’s access to vital, life‑saving treatments. This collaboration builds on DKSH’s existing partnerships with Pfizer in multiple markets in Southeast Asia further strengthening Pfizer’s footprint and execution capabilities across the region.
DKSH Malaysia has entered into a strategic partnership with AbbVie Sdn. Bhd. to provide commercial services for its leading ophthalmology portfolio within Malaysia’s pharmacy channel. This partnership builds on DKSH’s existing collaborations with AbbVie in Vietnam and Thailand, further strengthening AbbVie’s regional presence and commercial excellence in Asia’s eye care market.
DKSH has been recognized as a Great Place to Work® in 16 key markets, surpassing the number of certified markets in the previous year. DKSH has also been named one of the “Fortune 100 Best Companies to Work For™ Southeast Asia 2025”. These achievements reaffirm DKSH’s work environment and underscore its ongoing commitment to fostering a great corporate culture.
DKSH has entered a strategic partnership with medisana, a trusted global brand in home health and wellness solutions, to provide comprehensive commercial and logistics services for its medical devices portfolio across Malaysia and Brunei. This new collaboration leverages DKSH’s extensive distribution network and deep healthcare expertise to strengthen medisana’s presence in the pharmacy channel and support its continued expansion in Asia.
DKSH has announced Natale Capri as the sole Head of the Business Unit Performance Materials, building on his more than ten years of experience as Business Unit Co-Head. Thomas Sul, the former Co-Head, will transition into retirement.
DKSH has achieved another milestone in its sustainability efforts, as the Science Based Targets initiative (SBTi) has officially validated its near-term and net zero targets. This approval reflects DKSH’s commitment to its climate ambitions and reinforces its goal of achieving net-zero emissions by 2050.
DKSH has signed an agreement to acquire Biomedic Science Material Joint Stock Company (“Biomedic”), a leading distributor of equipment and reagents used in the biotechnology and diagnostic market in Vietnam. With this transaction, DKSH Technology further extends its scientific solutions business in line with the Business Unit’s strategy to solidify its position as a leading scientific solutions provider in Asia and Beyond.
Reach out to our Group Media Relations team for any inquiries.
Head, Investor and Media Relations & Sustainability, and Head, Finance Healthcare Own Brands
Manager, Group Media Relations
Contact us to discover new opportunities.